{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:17:47Z","timestamp":1774574267159,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institutes of Health, Department of Health and Human Services"},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.01.026","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T03:01:44Z","timestamp":1486609304000},"page":"1455-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of multivalent H2 influenza pandemic vaccines in mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Brian J.","family":"Lenny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Sonnberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela F.","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.01.026_b0005","unstructured":"WHO. Influenza. In: WHO, editor. Immunization, Vaccines and Biologicals WHO; 2008."},{"key":"10.1016\/j.vaccine.2017.01.026_b0010","unstructured":"CDC. Key Facts about Seasonal Flu Vaccine. In: CDC, editor. Influenza (Flu). Atlanta, GA, USA: CDC; 2015."},{"key":"10.1016\/j.vaccine.2017.01.026_b0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2017.01.026_b0020","unstructured":"WHO. Influenza Vaccines: WHO Position Paper. In: WHO, editor. Weekly Epidemiological Record: WHO; 2005. p. 279\u201387."},{"key":"10.1016\/j.vaccine.2017.01.026_b0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2017.01.026_b0030","series-title":"Current topics in microbiology and immunology","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/82_2014_387","article-title":"Avian influenza virus transmission to mammals","author":"Herfst SI","year":"2014"},{"key":"10.1016\/j.vaccine.2017.01.026_b0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","article-title":"Emergence and pandemic potential of swine-origin H1N1 influenza virus","volume":"459","author":"Neumann","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.01.026_b0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/515616","article-title":"Pandemic versus epidemic influenza mortality: a pattern of changing age distribution","volume":"178","author":"Simonsen","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00150-11","article-title":"Why do influenza virus subtypes die out? A hypothesis","volume":"2","author":"Palese","year":"2011","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.01.026_b0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/471157a","article-title":"Vaccinate for the next H2N2 pandemic now","volume":"471","author":"Nabel","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.01.026_b0055","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1128\/JVI.02526-13","article-title":"Risk assessment of H2N2 influenza viruses from the avian reservoir","volume":"88","author":"Jones","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0060","first-page":"113","article-title":"Analysis of internal proteins of influenza A (H2N2) viruses isolated from birds in East Germany in 1983","volume":"36","author":"Schafer","year":"1992","journal-title":"Acta Virol"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2017.01.026_b0065","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1099\/0022-1317-80-12-3167","article-title":"Transmission of Eurasian avian H2 influenza virus to shorebirds in North America","volume":"80","author":"Makarova","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0070","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/viro.1993.1319","article-title":"Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir","volume":"194","author":"Schafer","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.01.026_b0075","doi-asserted-by":"crossref","first-page":"20949","DOI":"10.1073\/pnas.0710286104","article-title":"Identification of H2N3 influenza A viruses from swine in the United States","volume":"104","author":"Ma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.01.026_b0080","doi-asserted-by":"crossref","first-page":"e39990","DOI":"10.1371\/journal.pone.0039990","article-title":"Recently emerged swine influenza A virus (H2N3) causes severe pneumonia in Cynomolgus macaques","volume":"7","author":"Richt","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.026_b0085","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1128\/JVI.02590-14","article-title":"Adaptation of pandemic H2N2 influenza A viruses in humans","volume":"89","author":"Joseph","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0090","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1128\/JVI.63.11.4603-4608.1989","article-title":"Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics","volume":"63","author":"Kawaoka","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0095","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4161\/hv.6.10.12915","article-title":"Pre-pandemic and pandemic influenza vaccines","volume":"6","author":"Rockman","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.01.026_b0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3201\/eid1201.051147","article-title":"Vaccines for pandemic influenza","volume":"12","author":"Luke","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(08)70232-9","article-title":"Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans","volume":"8","author":"Jennings","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0110","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1128\/JVI.00511-10","article-title":"Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0115","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1128\/JVI.01829-13","article-title":"Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets","volume":"88","author":"Chen","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1750-2659.2012.00350.x","article-title":"An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults","volume":"7","author":"Talaat","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2017.01.026_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2014.10.065","article-title":"Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates","volume":"33","author":"Broadbent","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.026_b0130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.vaccine.2008.11.100","article-title":"Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination","volume":"27","author":"Ohmit","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.026_b0135","unstructured":"WHO. Live attenuated vaccines (LAV). In: WHO, editor. Vaccine Safety Basics: e-learning Course, Module 2. Module 2 ed.: WHO."},{"key":"10.1016\/j.vaccine.2017.01.026_b0140","unstructured":"MedImmune. FluMist: Package Insert and Label Information; 2012."},{"key":"10.1016\/j.vaccine.2017.01.026_b0145","unstructured":"CDC. Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) In: CDC, editor. Influenza (Flu). Atlanta, GA: CDC; 2015."},{"key":"10.1016\/j.vaccine.2017.01.026_b0150","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1586\/14760584.2013.824709","article-title":"The evolving history of influenza viruses and influenza vaccines","volume":"12","author":"Hannoun","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.01.026_b0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI101633","article-title":"Protective effect of vaccination against induced influenza A","volume":"24","author":"Francis","year":"1945","journal-title":"J Clin Invest"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2017.01.026_b0160","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1086\/507544","article-title":"Vaccines for seasonal and pandemic influenza","volume":"194","author":"Nichol","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0165","first-page":"251","article-title":"Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype","volume":"41","author":"Govorkova","year":"1997","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0170","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s007050070109","article-title":"Cross-protection and reassortment studies with avian H2 influenza viruses","volume":"145","author":"Kaverin","year":"2000","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00430-002-0147-9","article-title":"Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines","volume":"191","author":"Hehme","year":"2002","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virusres.2004.02.029","article-title":"Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use","volume":"103","author":"Hehme","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.01.026_b0185","unstructured":"Control NIfBSa. Influenza Reagent Influenza Antigen A\/Singapore\/1\/57 (H2N2). In: Control NIfBSa, editor; 2008."},{"key":"10.1016\/j.vaccine.2017.01.026_b0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/S0022172400062860","article-title":"Antibody status to influenza A\/Singapore\/1\/57(H2N2) in Finland during a period of outbreaks caused by H3N2 and H1N1 subtype viruses","volume":"95","author":"Pyhala","year":"1985","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2017.01.026_b0195","first-page":"493","article-title":"A simple method for estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hygiene"},{"key":"10.1016\/j.vaccine.2017.01.026_b0200","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1016\/j.vaccine.2011.07.133","article-title":"Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine","volume":"29","author":"Jones","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.026_b0205","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1016\/j.vaccine.2007.01.083","article-title":"Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model","volume":"25","author":"Ninomiya","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.026_b0210","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/infdis\/175.2.352","article-title":"Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine","volume":"175","author":"Katz","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0215","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/CVI.00156-06","article-title":"Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza","volume":"13","author":"Huber","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0220","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/v7082821","article-title":"Characterization of humoral responses induced by an H7N9 influenza virus-like particle vaccine in BALB\/C mice","volume":"7","author":"Zhang","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.01.026_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12879-015-0838-7","article-title":"Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung","volume":"15","author":"Proudfoot","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/sji.12288","article-title":"Induction of local secretory IgA and multifunctional CD4(+) T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB\/c mice","volume":"81","author":"Trondsen","year":"2015","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0235","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1128\/JVI.02052-06","article-title":"Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus","volume":"81","author":"Quan","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0240","doi-asserted-by":"crossref","first-page":"11044","DOI":"10.1073\/pnas.1006419107","article-title":"Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry","volume":"107","author":"Kim","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.01.026_b0245","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0009-8981(91)90352-D","article-title":"An enzyme-linked lectin assay for sialidase","volume":"198","author":"Lambre","year":"1991","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.vaccine.2017.01.026_b0250","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/JVI.00078-15","article-title":"An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection","volume":"89","author":"Zanin","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0255","unstructured":"USDA. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. In: Research CfBEa, editor. U.S. Department of Health and Human Services; 2009."},{"key":"10.1016\/j.vaccine.2017.01.026_b0260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0270","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/14760584.7.6.783","article-title":"Animal models in influenza vaccine testing","volume":"7","author":"van der Laan","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.01.026_b0275","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/erv.13.35","article-title":"Immunological assessment of influenza vaccines and immune correlates of protection","volume":"12","author":"Reber","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.01.026_b0280","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/JVI.02162-09","article-title":"Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic","volume":"84","author":"Xu","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0285","doi-asserted-by":"crossref","first-page":"e11158","DOI":"10.1371\/journal.pone.0011158","article-title":"Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957","volume":"5","author":"Pappas","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.026_b0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virol.2015.01.002","article-title":"Assessment of transmission, pathogenesis and adaptation of H2 subtype influenza viruses in ferrets","volume":"477","author":"Pappas","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.01.026_b0295","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1080\/21645515.2015.1010859","article-title":"H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers","volume":"11","author":"Isakova-Sivak","year":"2015","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.01.026_b0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-385034-8.00003-X","article-title":"Influenza vaccines: the good, the bad, and the eggs","volume":"77","author":"Schultz-Cherry","year":"2010","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2017.01.026_b0305","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2017.01.026_b0310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2017.01.026_b0315","unstructured":"WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Geneva, Switzerland: WHO; 2015."},{"key":"10.1016\/j.vaccine.2017.01.026_b0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12879-015-1193-4","article-title":"Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom","volume":"15","author":"Thommes","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.vaccine.2014.10.079","article-title":"Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors","volume":"33","author":"Chit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.026_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)00249-2","article-title":"Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial","author":"Chit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0335","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3201\/eid0505.990507","article-title":"The economic impact of pandemic influenza in the United States: priorities for intervention","volume":"5","author":"Meltzer","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.026_b0340","unstructured":"WHO. Recommendations for the production and control of influenza vaccine (inactivated); 2005. p. 99-134. Report 927. <http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/influenza\/ANNEX%203%20InfluenzaP99-134.pdf?ua=1>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T03:56:12Z","timestamp":1601610972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17300610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17300610"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of multivalent H2 influenza pandemic vaccines in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}